Role of alpha-2 agonists in neuroprotection (Q35174036)

6 August 2017

1 reference

title

Role of alpha-2 agonists in neuroprotection (English)

1 reference

6 August 2017

Larry Wheeler

1

1 reference

6 August 2017

Elizabeth WoldeMussie

series ordinal

2

1 reference

6 August 2017

Ronald Lai

series ordinal

3

1 reference

6 August 2017

publication date

1 April 2003

1 reference

6 August 2017

published in

Survey of Ophthalmology

1 reference

6 August 2017

volume

48 Suppl 1

1 reference

6 August 2017

page(s)

S47-51

1 reference

Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Vitreous concentration of topically applied brimonidine tartrate 0.2%.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

TUNEL-positive ganglion cells in human primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

In situ detection of apoptosis in normal pressure glaucoma. a preliminary examination

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Is neuroprotection a viable therapy for glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900004-3

7 January 2021

10.1016/S0039-6257(03)00004-3

Identifiers

DOI

1 reference

release_qksoezinzndpfplhcrlzuq6e7e

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qksoezinzndpfplhcrlzuq6e7e

24 November 2022

mapped directly with Wikidata item

1 reference